Biotech Stocks Facing FDA Decision In December


Roche’s (RHHBY.OB) supplemental Biologics License Application seeking approval for Tecentriq in combination with Avastin, paclitaxel and carboplatin for
the first-line treatment of people with metastatic non-squamous non-small cell lung cancer awaits the FDA decision on December 5, 2018.

Tecentriq is already approved in the European Union, United States and more than 70 countries for people with previously treated metastatic non-small cell lung cancer and for certain types of untreated or previously treated metastatic urothelial carcinoma (mUC), the most common type of bladder cancer.

In the first half of 2018, Tecentriq generated sales of 320 million Swiss francs, up 37% over the comparable year-ago period.

RHHBY.OB closed Friday's (Nov.23) trading at $31.05, up 0.11%.